Medtronic has already begun recruiting patients for the trial, which could include up to 50 sites and 1,000 patients. The company is also in the process of enrolling patients in a separate clinical trial, approved in 2017, that examines Infuse for posterolateral fusions.
The FDA and Medtronic are working together to incorporate retrospective safety and efficacy data into the PLF clinical trial. Infuse originally hit the market in 2002 and has been used in 2 million patients since then.
“Medtronic continues to invest in scientific evidence on Infuse to continue adding to the growing body of clinical data, and we believe these trials will generate additional data to expand indications, increase access to surgeons and alleviate pain and restore health for patients around the world,” said Jacob Paul, senior vice president and president of Medtronic’s spine division in the Restorative Therapies Group.
Both clinical trials are investigational only.
Infuse is a bone morphogenetic protein product, rhBMP-2. According to Grand View Research, the BMP market was valued at $504.2 million in 2015, but expected to grow through 2024.
For the first quarter of the 2020 fiscal year, Infuse sales grew in the low-double digits.
More articles on spine surgery:
Medtronic to launch 4 spine surgery products, enhance Mazor X Stealth Edition
Spine surgery utilization, cost in the US: 5 key findings
DePuy Synthes launches degenerative spine disease implant platform
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.